About
Company Overview
Trustlife is a pioneering biotechnology company that leverages artificial intelligence and systems biology to transform drug discovery. Our innovative approach integrates multi-omics data analysis with advanced computational methods to accelerate the development of novel therapeutics across major therapeutic areas.
Our research is powered by one of the world's largest and highest-quality multi-omics datasets, derived from over 20,000 human cohorts and strategic partnerships including the Human Protein Atlas. Trustlife addresses major therapeutic areas including neurodegenerative diseases (Alzheimer's, Parkinson's), cancer (prostate, brain, pancreatic, breast, lung, colon, etc.), inflammatory diseases, and muscle-wasting disorders. We are also developing a Cancer Immunotherapy project that is currently in early stages of development. Rather than treating diseases as isolated issues, we emphasize a holistic understanding of the human body, recognizing the importance of interconnected biological systems and the role of microbiome-host interactions. This comprehensive approach enables the discovery of novel drug targets and the development of first-in-class therapeutic compounds.
Trustlife is backed by strong financial and institutional support, with $21M in raised capital and a $100M+ valuation. Our leadership includes internationally renowned scientists and executives with decades of experience in drug discovery and commercialization.
Our Assets
Pioneering the future of drug discovery through cutting-edge technology, innovative research, and state-of-the-art facilities.
Advanced AI Platforms
Our platform features:
- Integration of multi-omics data (proteomics, metabolomics, transcriptomics, oral & gut microbiome)
- AI-based & data-driven modeling of disease and drug interactions
- Validated systems biology-based repositioning approaches
- Confidence-driven drug-target ranking with an extensive drug screening library
Drug Candidates
Trustlife currently holds a pipeline of 14 candidate molecules, with 3 in Phase 1 clinical trials as of 2025, including:
- Neurodegenerative Diseases: Compounds targeting pathways beyond amyloid and tau (Alzheimer's, Parkinson's)
- Oncology: Innovative drugs against prostate, brain, kidney, pancreatic, colon, breast and lung cancers
- Inflammatory Diseases: Novel mPGES-1 inhibitors targeting prostaglandin E2 pathway for Endometriosis and Rheumatoid Arthritis
- Metabolic Disorders: FDA approved drugs targeting key genes in Muscle Sarcopenia, NAFLD and NASH
State-of-the-Art Preclinical R&D Center
Trustlife's preclinical research is anchored in its certified R&D center in Istanbul. With a $5M investment and a 1,500 m² lab space, the center supports high-throughput, AI-integrated drug development.
- 60+ highly qualified scientists, including 24 PhDs, across four specialized labs
- 14-project parallel capacity, enabling simultaneous preclinical studies
- Green chemistry strategies in our Medicinal Chemistry Lab with 27 synthesis stations
- Validated data workflows, cross-checked by partners at KTH Sweden and Chieti Pescara University Italy
- AI-enhanced drug design in the Computational Chemistry & Biology Lab